News – Page 222 – Endpoints News

Bluebird is still looking for more financing as it brings sickle cell therapy to market: #JPM24

Last year

After 'growing up' last year, Moderna warns of losses and charts path back to profits: #JPM24

Last year

Catalent touts GLP-1 manufacturing; Telix grows radiopharma capacity; Arcturus expands in Japan: #JPM24

Last year

FDA's CBER chief hints at expanding Sarepta's gene therapy label, sends stock up 25%

Last year

Aclaris' mixed PhIIb eczema data; Amgen licenses Xeris' tech; Bolden Tx secures funding

Last year

Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyout

Last year

C4 Therapeutics cuts staff, restructures to focus on lead protein degradation programs, discovery pacts

Last year

LinkedUp, TianTi end legal dispute with Adimab over yeast-based antibody platform

Last year

CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinic

Last year

Alcon touts PhIII win for dry eye drug, plans mid-2024 FDA filing

Last year

Walgreens’ new CEO unpacks how the chain will survive as a standalone business: #JPM24

Last year

Walgreens CEO says it would be easy for UK pharmacy operation Boots to run separately amid talks of splitting: #JPM24

Last year

Paul Hudson is 'open-minded' to M&A as he plots Sanofi's transformation: #JPM24

Last year

#JPM24 quick hits: Vibe check; Maze’s next turn; AI at pharma companies + more

Last year

Healthcare giant Grifols accused of manipulating finances by short seller Gotham City, stock plummets

Last year

Lupus drug market growing as physicians adopt newer options — and look for more, research finds

Last year

FDA chief taps Elizabeth Jungman as new chief of staff, starting later this month

Last year

As Congress debates orphan reforms, new analysis finds 65% of orphan drugs approved for a single rare disease

Last year

MiMedx receives FDA warning letter over Axiofill manufacturing concerns

Last year

Illumina reports stronger-than-expected growth, indicates Grail divestiture still in early stages: #JPM24

Last year

Merck is eyeing new immunology deals, chief medical officer says: #JPM24

Last year

Novartis CEO plays down Cytokinetics buyout rumors in CNBC interview

Last year

TG licenses Precision's cell therapy; Innovent's PhIII weight loss win; Atea's positive hep C data

Last year

Lantheus hands Perspective Therapeutics $28M upfront to expand its radiopharma options

Last year

First page Previous page 219 220 221222223 224 225 Next page Last page